Cargando…

Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients

Multiple myeloma (MM) is a hematologic cancer defined by an abnormal development of clonal plasma cells in the bone marrow, releasing vast quantities of immunoglobulins and different proteins. In the majority of patients, MM remains incurable despite decades of medical improvement and a number of tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Potre, Cristina, Borsi, Ema, Potre, Ovidiu, Samfireag, Miruna, Costachescu, Dan, Cerbu, Bianca, Bratosin, Felix, Secosan, Cristina, Negrean, Rodica Anamaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689544/
https://www.ncbi.nlm.nih.gov/pubmed/36354730
http://dx.doi.org/10.3390/curroncol29110670
_version_ 1784836561839325184
author Potre, Cristina
Borsi, Ema
Potre, Ovidiu
Samfireag, Miruna
Costachescu, Dan
Cerbu, Bianca
Bratosin, Felix
Secosan, Cristina
Negrean, Rodica Anamaria
author_facet Potre, Cristina
Borsi, Ema
Potre, Ovidiu
Samfireag, Miruna
Costachescu, Dan
Cerbu, Bianca
Bratosin, Felix
Secosan, Cristina
Negrean, Rodica Anamaria
author_sort Potre, Cristina
collection PubMed
description Multiple myeloma (MM) is a hematologic cancer defined by an abnormal development of clonal plasma cells in the bone marrow, releasing vast quantities of immunoglobulins and different proteins. In the majority of patients, MM remains incurable despite decades of medical improvement and a number of treatment breakthroughs. Frontline standard-of-care has little long-term success, with the majority of patients eventually relapsing, although the overall progression-free survival (PFS) has improved significantly in the last ten years. Patients who are eligible for a transplant have the highest PFS rate at 5 years, depending on medication response and other various factors that are yet to be discovered. Therefore, the current study aimed to evaluate the response to VCD (bortezomib, cyclophosphamide, dexamethasone) and VTD (bortezomib, thalidomide, dexamethasone) used as pretransplant regimens, as well as to compare responses between thalidomide and lenalidomide used as maintenance therapy posttransplant. This retrospective study was performed on a group of 105 hospitalized patients in the Hematology Department of the Timisoara Municipal Emergency Clinical Hospital between January 2016 and December 2021. Data was collected from the paper records of patients with MM who were under-followed. The treatment regimens used as induction therapy were either VCD or VTD if cyclophosphamide was contraindicated. Of the 105 patients, 27 became eligible for bone marrow transplantation. Furthermore, they received maintenance therapy which was based on either lenalidomide with dexamethasone or thalidomide with dexamethasone. Of the 62 patients treated with VTD, 17.7% were in complete remission before stem cell transplantation. Of the 43 patients treated with VCD, 37.2% were in complete remission. The 5-year mean progression-free survival (PFS) in the entire cohort was better in the group treated with the VTD regimen (31.6 vs. 27.2 months). However, in the 27 patients undergoing maintenance after ASCT, the PFS with thalidomide was 35.5 months (95% CI = 27–42), while the PFS rate in those receiving maintenance treatment with lenalidomide was 46.1 months (95% CI = 20–73). VCD proved to be superior to VTD in inducing complete pretransplant responses. Regarding maintenance therapy, patients from the lenalidomide group had superior responses compared with those under thalidomide.
format Online
Article
Text
id pubmed-9689544
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96895442022-11-25 Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients Potre, Cristina Borsi, Ema Potre, Ovidiu Samfireag, Miruna Costachescu, Dan Cerbu, Bianca Bratosin, Felix Secosan, Cristina Negrean, Rodica Anamaria Curr Oncol Article Multiple myeloma (MM) is a hematologic cancer defined by an abnormal development of clonal plasma cells in the bone marrow, releasing vast quantities of immunoglobulins and different proteins. In the majority of patients, MM remains incurable despite decades of medical improvement and a number of treatment breakthroughs. Frontline standard-of-care has little long-term success, with the majority of patients eventually relapsing, although the overall progression-free survival (PFS) has improved significantly in the last ten years. Patients who are eligible for a transplant have the highest PFS rate at 5 years, depending on medication response and other various factors that are yet to be discovered. Therefore, the current study aimed to evaluate the response to VCD (bortezomib, cyclophosphamide, dexamethasone) and VTD (bortezomib, thalidomide, dexamethasone) used as pretransplant regimens, as well as to compare responses between thalidomide and lenalidomide used as maintenance therapy posttransplant. This retrospective study was performed on a group of 105 hospitalized patients in the Hematology Department of the Timisoara Municipal Emergency Clinical Hospital between January 2016 and December 2021. Data was collected from the paper records of patients with MM who were under-followed. The treatment regimens used as induction therapy were either VCD or VTD if cyclophosphamide was contraindicated. Of the 105 patients, 27 became eligible for bone marrow transplantation. Furthermore, they received maintenance therapy which was based on either lenalidomide with dexamethasone or thalidomide with dexamethasone. Of the 62 patients treated with VTD, 17.7% were in complete remission before stem cell transplantation. Of the 43 patients treated with VCD, 37.2% were in complete remission. The 5-year mean progression-free survival (PFS) in the entire cohort was better in the group treated with the VTD regimen (31.6 vs. 27.2 months). However, in the 27 patients undergoing maintenance after ASCT, the PFS with thalidomide was 35.5 months (95% CI = 27–42), while the PFS rate in those receiving maintenance treatment with lenalidomide was 46.1 months (95% CI = 20–73). VCD proved to be superior to VTD in inducing complete pretransplant responses. Regarding maintenance therapy, patients from the lenalidomide group had superior responses compared with those under thalidomide. MDPI 2022-11-08 /pmc/articles/PMC9689544/ /pubmed/36354730 http://dx.doi.org/10.3390/curroncol29110670 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Potre, Cristina
Borsi, Ema
Potre, Ovidiu
Samfireag, Miruna
Costachescu, Dan
Cerbu, Bianca
Bratosin, Felix
Secosan, Cristina
Negrean, Rodica Anamaria
Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients
title Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients
title_full Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients
title_fullStr Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients
title_full_unstemmed Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients
title_short Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients
title_sort assessing pretransplant and posttransplant therapy response in multiple myeloma patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689544/
https://www.ncbi.nlm.nih.gov/pubmed/36354730
http://dx.doi.org/10.3390/curroncol29110670
work_keys_str_mv AT potrecristina assessingpretransplantandposttransplanttherapyresponseinmultiplemyelomapatients
AT borsiema assessingpretransplantandposttransplanttherapyresponseinmultiplemyelomapatients
AT potreovidiu assessingpretransplantandposttransplanttherapyresponseinmultiplemyelomapatients
AT samfireagmiruna assessingpretransplantandposttransplanttherapyresponseinmultiplemyelomapatients
AT costachescudan assessingpretransplantandposttransplanttherapyresponseinmultiplemyelomapatients
AT cerbubianca assessingpretransplantandposttransplanttherapyresponseinmultiplemyelomapatients
AT bratosinfelix assessingpretransplantandposttransplanttherapyresponseinmultiplemyelomapatients
AT secosancristina assessingpretransplantandposttransplanttherapyresponseinmultiplemyelomapatients
AT negreanrodicaanamaria assessingpretransplantandposttransplanttherapyresponseinmultiplemyelomapatients